vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and HARTE HANKS INC (HHS). Click either name above to swap in a different company.
AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $39.9M, roughly 1.1× HARTE HANKS INC). HARTE HANKS INC runs the higher net margin — 5.5% vs -19.9%, a 25.5% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -15.4%). HARTE HANKS INC produced more free cash flow last quarter ($-686.0K vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -6.4%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.
ABCL vs HHS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $39.9M |
| Net Profit | $-8.9M | $2.2M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | -0.3% |
| Net Margin | -19.9% | 5.5% |
| Revenue YoY | 788.4% | -15.4% |
| Net Profit YoY | 73.9% | — |
| EPS (diluted) | $-0.03 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $39.9M | ||
| Q3 25 | $9.0M | $39.5M | ||
| Q2 25 | $17.1M | $38.6M | ||
| Q1 25 | $4.2M | $41.6M | ||
| Q4 24 | $5.0M | $47.1M | ||
| Q3 24 | $6.5M | $47.6M | ||
| Q2 24 | $7.3M | $45.0M | ||
| Q1 24 | $10.0M | $45.4M |
| Q4 25 | $-8.9M | $2.2M | ||
| Q3 25 | $-57.1M | $-2.3M | ||
| Q2 25 | $-34.7M | $-335.0K | ||
| Q1 25 | $-45.6M | $-392.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-51.1M | $142.0K | ||
| Q2 24 | $-36.9M | $-27.8M | ||
| Q1 24 | $-40.6M | $-171.0K |
| Q4 25 | -63.7% | -0.3% | ||
| Q3 25 | -851.8% | 1.3% | ||
| Q2 25 | -290.2% | 0.1% | ||
| Q1 25 | -1479.6% | -0.1% | ||
| Q4 24 | — | -3.3% | ||
| Q3 24 | -1439.4% | 4.0% | ||
| Q2 24 | -1276.2% | 3.0% | ||
| Q1 24 | -551.5% | 0.8% |
| Q4 25 | -19.9% | 5.5% | ||
| Q3 25 | -637.8% | -5.8% | ||
| Q2 25 | -203.3% | -0.9% | ||
| Q1 25 | -1077.2% | -0.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -785.4% | 0.3% | ||
| Q2 24 | -504.3% | -61.8% | ||
| Q1 24 | -408.0% | -0.4% |
| Q4 25 | $-0.03 | $0.30 | ||
| Q3 25 | $-0.19 | $-0.31 | ||
| Q2 25 | $-0.12 | $-0.05 | ||
| Q1 25 | $-0.15 | $-0.05 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | $-0.17 | $0.02 | ||
| Q2 24 | $-0.13 | $-3.84 | ||
| Q1 24 | $-0.14 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $5.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $20.5M |
| Total Assets | $1.4B | $91.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $5.6M | ||
| Q3 25 | $83.2M | $6.5M | ||
| Q2 25 | $92.4M | $4.8M | ||
| Q1 25 | $159.3M | $9.0M | ||
| Q4 24 | $156.3M | $9.8M | ||
| Q3 24 | $126.6M | $5.9M | ||
| Q2 24 | $148.3M | $11.0M | ||
| Q1 24 | $123.6M | $11.5M |
| Q4 25 | $966.9M | $20.5M | ||
| Q3 25 | $964.0M | $19.9M | ||
| Q2 25 | $1.0B | $22.2M | ||
| Q1 25 | $1.0B | $21.4M | ||
| Q4 24 | $1.1B | $21.7M | ||
| Q3 24 | $1.1B | $21.0M | ||
| Q2 24 | $1.1B | $20.6M | ||
| Q1 24 | $1.1B | $20.0M |
| Q4 25 | $1.4B | $91.8M | ||
| Q3 25 | $1.4B | $92.7M | ||
| Q2 25 | $1.4B | $95.0M | ||
| Q1 25 | $1.3B | $100.6M | ||
| Q4 24 | $1.4B | $101.8M | ||
| Q3 24 | $1.4B | $108.1M | ||
| Q2 24 | $1.4B | $109.7M | ||
| Q1 24 | $1.5B | $113.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $737.0K |
| Free Cash FlowOCF − Capex | $-44.6M | $-686.0K |
| FCF MarginFCF / Revenue | -99.4% | -1.7% |
| Capex IntensityCapex / Revenue | 21.9% | 3.6% |
| Cash ConversionOCF / Net Profit | — | 0.33× |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $-4.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $737.0K | ||
| Q3 25 | $-52.6M | $3.2M | ||
| Q2 25 | $-32.4M | $-4.8M | ||
| Q1 25 | $-11.6M | $-818.0K | ||
| Q4 24 | $-108.6M | $4.0M | ||
| Q3 24 | $-28.9M | $-2.9M | ||
| Q2 24 | $-30.0M | $1.6M | ||
| Q1 24 | $-41.7M | $-5.7M |
| Q4 25 | $-44.6M | $-686.0K | ||
| Q3 25 | $-61.5M | $2.2M | ||
| Q2 25 | $-45.8M | $-5.1M | ||
| Q1 25 | $-22.2M | $-923.0K | ||
| Q4 24 | $-187.0M | $3.4M | ||
| Q3 24 | $-47.4M | $-4.9M | ||
| Q2 24 | $-50.1M | $926.0K | ||
| Q1 24 | $-65.8M | $-6.2M |
| Q4 25 | -99.4% | -1.7% | ||
| Q3 25 | -687.0% | 5.5% | ||
| Q2 25 | -267.9% | -13.1% | ||
| Q1 25 | -524.0% | -2.2% | ||
| Q4 24 | -3702.8% | 7.3% | ||
| Q3 24 | -728.4% | -10.2% | ||
| Q2 24 | -683.8% | 2.1% | ||
| Q1 24 | -661.5% | -13.7% |
| Q4 25 | 21.9% | 3.6% | ||
| Q3 25 | 99.7% | 2.5% | ||
| Q2 25 | 78.2% | 0.6% | ||
| Q1 25 | 251.1% | 0.3% | ||
| Q4 24 | 1552.7% | 1.3% | ||
| Q3 24 | 284.6% | 4.0% | ||
| Q2 24 | 274.6% | 1.5% | ||
| Q1 24 | 242.5% | 1.2% |
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -20.76× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
